author-photo

Dieter Hoersch

30

Papers

340

Citations

Citation Trend

Filter By

Papers (23) Sort By

Journal Conference Others

A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms.

2021 International Journal of Medical Sciences
Show All
- Source
- Cite
- Save
Citations (2)
S2k-Leitlinie Neuroendokrine Tumore. AWMF-Reg. 021-27

2018 Zeitschrift Fur Gastroenterologie
Show All
- Source
- Cite
- Save
Citations (6)
P3497Carcinoid heart disease in patients with neuroendocrine tumours: prevalence and predisposing factors

2018 European Heart Journal
Show All
- Source
- Cite
- Save
Citations (0)
232TiP Lanreotide autogel/depot in lung neuroendocrine tumours: The randomized, double-blind, placebo-controlled, international phase 3 SPINET Study

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
PUB119 Lanreotide in Patients with Lung Neuroendocrine Tumors: The Randomized Double-Blind Placebo-Controlled International Phase 3 SPINET Study

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (2)
439PDPeptide receptor radionuclide therapy of neuroendocrine neoplasms using lutetium-177 and yttrium-90 labeled somatostatin analogs: A single center experience in over 1000 patients

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (17)
Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome : Patient Exit Interviews

2016 Pancreas
Show All
- Source
- Cite
- Save
Citations (2)
Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial

2016 Pancreas
Show All
- Source
- Cite
- Save
Citations (0)
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET)

2012 Pancreas
Show All
- Source
- Cite
- Save
Citations (4)